![Ralph Charlton](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Ralph Charlton
Hoofd Techniek/Wetenschap/O&O bij
POLARYX THERAPEUTICS, INC.
Profiel
Ralph William Charlton is Chief Medical Officer at Polaryx Therapeutics, Inc. since 2026.
Former roles include Executive Medical Director at Allergan, Inc. from 2018 to 2019, Senior Medical Director-Clinical Development at Ascendis Pharma, Inc. from 2019 to 2020, Vice President-Clinical Development at 89bio, Inc. from 2020 to 2022, Chief Medical Officer at Spruce Biosciences, Inc. from 2022 to 2024, and SVP-Clinical Development & Skeletal Dysplasia at Tyra Biosciences, Inc. Education includes undergraduate studies at the University of the Pacific, graduate studies at The University of California, San Francisco, and a doctorate from the Keck School of Medicine of USC.
Actieve functies van Ralph Charlton
| Bedrijven | Functie | Begin |
|---|---|---|
| POLARYX THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-09-2026 |
Eerdere bekende functies van Ralph Charlton
| Bedrijven | Functie | Einde |
|---|---|---|
| SPRUCE BIOSCIENCES, INC. | Hoofd Techniek/Wetenschap/O&O | 20-12-2024 |
| 89BIO, INC. | Hoofd Techniek/Wetenschap/O&O | 01-02-2022 |
Ascendis Pharma, Inc.
 Ascendis Pharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops endocrinology, rare disease and oncology medicines & transient conjugation platform | Hoofd Techniek/Wetenschap/O&O | 01-11-2020 |
| ALLERGAN, INC. | Hoofd Techniek/Wetenschap/O&O | 01-05-2019 |
| TYRA BIOSCIENCES, INC. | Corporate Officer/Principal | - |
Opleiding van Ralph Charlton
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
26
Eerstegraads connecties
9
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 9 |
|---|---|
Allergan, Inc.
 Allergan, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
University of the Pacific
 University of the Pacific Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of California, San Francisco
 The University of California, San Francisco Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Keck School of Medicine of USC
 Keck School of Medicine of USC Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ascendis Pharma, Inc.
Ascendis Pharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops endocrinology, rare disease and oncology medicines & transient conjugation platform | Health Technology |
Spruce Biosciences, Inc.
 Spruce Biosciences, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders | Health Technology |
89bio, Inc.
 89bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
Tyra Biosciences, Inc.
 Tyra Biosciences, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops cancer treatment drug therapies | Health Technology |
Polaryx Therapeutics, Inc.
 Polaryx Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical-stage biotechnology company that engages in discovery, development and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders | Commercial Services |
